EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Impact of Infections in Patients Treated with Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma

Abdullah Esmail iD, Jiaqiong Xu, Ethan A Burns, Karen Abboud, Ali Sheikh, Godsfavour Umoru, Kelly Gee, Catherine Wiechmann, Yuqi Zhang, Maen Abdelrahim

Journal of Clinical Medicine · 23.08.2024 · 13 (17) · 4994

DOI: 10.3390/jcm13174994 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 23.08.2024. Verfasst von Abdullah Esmail und 9 weiteren Autor:innen. Beteiligte Einrichtung: Houston Methodist Neal Cancer Center, Houston Methodist Hospital, Houston, TX 77030, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The therapeutic landscape of unresectable hepatocellular carcinoma (uHCC) continues to evolve. Atezolizumab, an anti-programmed cell death ligand 1 (PD-1) immune checkpoint inhibitor (ICI), in combination with bevacizumab, has substantially improved outcomes. This study aims to evaluate the incidence, risk factors, and outcomes in patients who develop infections while receiving atezolizumab and bevacizumab for uHCC.

Methods

Patients who received atezolizumab and bevacizumab for uHCC at a single hospital network were included. Types and rates of infections were reported. Covariates compared among infected and non-infected cohorts included age, sex, race, comorbidities, Eastern Cooperative Oncology Group (ECOG) performance status, immunosuppressive use, chronic infections, number of cycles of ICIs given, antibiotic or antiviral therapies at ICI initiation, and line of therapy (first-line, second-line, greater than second-line).

Results

Out of 810 evaluable patients, 34 uHCC patients were treated with atezolizumab plus bevacizumab. The mean ± SD age was 66.29 ± 9.39; 28 (82.35%) were males. There were 17 (50%) patients with reported infection, with bacterial infection occurring in 12 (70.59%) patients and COVID-19 in 4 (23.5%). Of the infected patients, eight (47.06%) had one infection, five (29.41%) had two infections, and two (11.76%) had three or more infections. Infected and non-infected patients received a median of 12 (IQR: 5–17) and 4 (IQR: 3–12) ICI cycles (p = 0.18), respectively. Infections did not negatively impact OS or PFS but resulted in treatment delays and discontinuation in 11 (64.71%) and 7 (41.18%) patients, respectively. At the last follow-up, 19 (55.88%) patients died, 9 (52.94%) in the non-infected group vs. 10 (58.82%) in the infected group (p = 1.0).

Conclusions

While a broad array of infections occurred in 50% of the patients in this cohort, it did not negatively impact survival outcomes. However, it did impact morbidity, with more all-cause admissions and treatment delays.

Schlagwörter

Stichwörter der Autor:innen

adverse eventsatezolizumabbevacizumabhepatocellular carcinomaimmune-relatedrisk factors

Autor:innen und Institutionen

  • Houston Methodist Neal Cancer Center, Houston Methodist Hospital, Houston, TX 77030, USA.
  • Department of Medicine, Houston Methodist Hospital, Houston, TX 77030, USA.

ORCID-Profile: Abdullah Esmail

Zitieren

APA

Esmail, A., Xu, J., Burns, E. A., Abboud, K., Sheikh, A., Umoru, G., Gee, K., Wiechmann, C., Zhang, Y., & Abdelrahim, M. (2024). The Impact of Infections in Patients Treated with Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma. Journal of Clinical Medicine, 13(17), 4994. https://doi.org/10.3390/jcm13174994

Vancouver

Esmail A, Xu J, Burns EA, Abboud K, Sheikh A, Umoru G, et al. The Impact of Infections in Patients Treated with Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma. Journal of Clinical Medicine. 2024;13(17):4994. doi:10.3390/jcm13174994

BibTeX
@article{Esmail2024,
  author = {Esmail, Abdullah and Xu, Jiaqiong and Burns, Ethan A and Abboud, Karen and Sheikh, Ali and Umoru, Godsfavour and Gee, Kelly and Wiechmann, Catherine and Zhang, Yuqi and Abdelrahim, Maen},
  title = {The Impact of Infections in Patients Treated with Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma},
  journal = {Journal of Clinical Medicine},
  year = {2024},
  volume = {13},
  number = {17},
  pages = {4994},
  doi = {10.3390/jcm13174994}
}
Kostenlos starten →